Clinical Trial Update: A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62% [Phase 3]

View source ↗

Summary

This clinical trial update notes a Phase III randomized, double-blind, placebo-controlled, multicenter study in men with acquired hypogonadotropic hypogonadism …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypogonadotropic Hypogonadism

Drugs mentioned

• AndroGel 1.62% (testosterone)
• Androxal (enclomiphene citrate)

Snippet

Sponsor: Repros Therapeutics Inc. | Conditions: Secondary Hypogonadism | Phase 3 | Status: COMPLETED